Kuros Biosciences AG (CSBTF)
| Previous close | 2.5500 |
| Open | 2.5500 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 2.5500 - 2.5500 |
| 52-week range | 2.0000 - 3.1000 |
| Volume | |
| Avg. volume | 193 |
| Market cap | 83.625M |
| Beta (5Y monthly) | 1.02 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.1920 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Kuros Biosciences Reports Continued Increase in MagnetOs U.S. Sales
Ad hoc announcement pursuant to Article 53 of the SIX listing rulesMagnetOs U.S. YTD sales increase 119% in 2021 compared to 2020Kuros expanding MagnetOs range to increase perioperative solutions for surgeons SCHLIEREN (ZURICH), Switzerland, Oct. 26, 2021 (GLOBE NEWSWIRE) -- Kuros Biosciences (“Kuros” or the “Company”), a leader in next generation bone graft technologies, today provided an update on its commercial activities. Direct sales of MagnetOs in the U.S. continued to accelerate in Q3 202
- GlobeNewswire
Kuros Biosciences to Showcase New MagnetOs Products at NASS 2021 Annual Meeting
New products expand perioperative solutions for surgeonsData to be presented on new formulation of MagnetOs that includes a collagen carrier SCHLIEREN (ZURICH), Switzerland, Sept. 28, 2021 (GLOBE NEWSWIRE) -- Kuros Biosciences (“Kuros” or the “Company”), a leader in next generation bone graft technologies, announced today that it will showcase new products in the MagnetOs range at the 36th Annual Meeting of the North American Spine Society (NASS), being held in Boston from September 29 to Octobe
- GlobeNewswire
Kuros to receive $7 million up front and potentially $166.5 million in future revenues under a royalty purchase agreement with XOMA related to Kuros’s license agreement with Checkmate Pharmaceuticals
Ad hoc announcement pursuant to Article 53 of the SIX listing rulesSCHLIEREN (ZURICH), Switzerland, July 15, 2021 (GLOBE NEWSWIRE) -- Kuros Biosciences AG (“Kuros” or the “Company”), a leader in next generation bone graft technologies, announced today that it has entered into a royalty purchase agreement with XOMA Corporation (NASDAQ: XOMA) under which XOMA has purchased a proportion of the potential future pre-commercial milestone payments and all the potential royalties due under the existing
